962 / 1266
Conclusions
•
MEK inhibitors are exciting new agents for low grade
gliomas.
•
Imaging responses can be documented after prolonged
exposure to therapy (4-6 months)
•
BRAF V600E specific inhibitors being tested in low-grade
and high-grade gliomas; responses have been observed in
patients with progressive disease
•
Phase I/II studies ongoing with mTOR inhibitors, BRAF
V600E inhibitors; MEK inhibitors and combination of BRAF
inhibitors and MEK inhibitors
•
New paradigm for treatment of LGG that uses tumor
biology to direct therapy